Raymond Iezzi

Dr. Raymond Iezzi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Ophthalmology
Verified
Journal Article
Closed access
RIRaymond Iezzi
Raymond Iezzi
KKKapil G. Kapoor
Kapil G. Kapoor

1 August 2010 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
IGInna V. Glybina
Inna V. Glybina
AKAlexander Kennedy
Alexander Kennedy
PAPaul Ashton
Paul Ashton
GAGary W. Abrams
Gary W. Abrams
RIRaymond Iezzi
Raymond Iezzi
Purpose.: To study the neuroprotective properties of low-dose, sustained-release intravitreous fluocinolone acetonide (FA) in transgenic S334ter-4 rats. Methods.: S334ter-4 rats aged 4 weeks were divided into four groups: 0.5 μg/d FA-loaded intravitreous drug delivery implant (IDDI); 0.2 μg/d FA-loaded IDDI; inactive IDDI; and unoperated controls. Electroretinography (ERG) was performed before surgery and every 2 weeks after surgery for 8 weeks. When the rats were 12 weeks of age, outer nuclear layer (ONL) and inner nuclear layer (INL) thicknesses were measured. Microglial cell counts were obtained from retinal wholemounts labeled for Iba-1. Results.: At the end of the study, unoperated and inactive IDDI-implanted rats demonstrated 50% to 60% reductions in ERG amplitudes compared with those recorded at 4 weeks (P < 0.001 for both groups). FA 0.2-μg/d animals demonstrated 15% amplitude attenuation, while FA 0.5-μg/d animals showed 30% reduction. ONL thickness in FA 0.2-μg/d–treated eyes was 25.8% ± 2.3% higher than in control group eyes (P < 0.001) and 30.0% ± 2.1% higher than in inactive IDDI-implanted eyes (P < 0.001). In FA 0.5-μg/d–treated eyes, ONL thickness was 22.4% ± 2.8% higher than in control group eyes (P < 0.001) and 22.3% ± 3.7% higher than in inactive IDDI-implanted eyes (P < 0.01). No statistically significant difference was observed between the two control groups. No statistically significant difference between the two FA-treated groups was found. FA-treated groups demonstrated significantly fewer activated microglial cells than control groups. Conclusions.: Chronic intravitreous infusion of FA preserves ONL cell morphology and ERG a- and b-wave amplitudes and reduces retinal neuroinflammation in S334ter rats. Based on these findings, the synthetic corticosteroid FA may promise a therapeutic role in patients with retinal degeneration.

1 July 2017 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
KVKevin K. Veverka
Kevin K. Veverka
SHSarah R. Hatt
Sarah R. Hatt
DLDavid A. Leske
David A. Leske
WBWilliam L. Brown
William L. Brown
RIRaymond Iezzi
Raymond Iezzi
JHJonathan M. Holmes
Jonathan M. Holmes

1 February 2024 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
TBTyler Bahr
Tyler Bahr
TVTruong A. Vu
Truong A. Vu
JTJared J. Tuttle
Jared J. Tuttle
RIRaymond Iezzi
Raymond Iezzi
Purpose: Retinal images contain rich biomarker information for neurodegenerative disease. Recently, deep learning models have been used for automated neurodegenerative disease diagnosis and risk prediction using retinal images with good results. Methods: In this review, we systematically report studies with datasets of retinal images from patients with neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others. We also review and characterize the models in the current literature which have been used for classification, regression, or segmentation problems using retinal images in patients with neurodegenerative diseases. Results: Our review found several existing datasets and models with various imaging modalities primarily in patients with Alzheimer's disease, with most datasets on the order of tens to a few hundred images. We found limited data available for the other neurodegenerative diseases. Although cross-sectional imaging data for Alzheimer's disease is becoming more abundant, datasets with longitudinal imaging of any disease are lacking. Conclusions: The use of bilateral and multimodal imaging together with metadata seems to improve model performance, thus multimodal bilateral image datasets with patient metadata are needed. We identified several deep learning tools that have been useful in this context including feature extraction algorithms specifically for retinal images, retinal image preprocessing techniques, transfer learning, feature fusion, and attention mapping. Importantly, we also consider the limitations common to these models in real-world clinical applications. Translational Relevance: This systematic review evaluates the deep learning models and retinal features relevant in the evaluation of retinal images of patients with neurodegenerative disease.

1 September 2018 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SMSasha A. Mansukhani
Sasha A. Mansukhani
ABAndrew J. Barkmeier
Andrew J. Barkmeier
SBSophie J. Bakri
Sophie J. Bakri
RIRaymond Iezzi
Raymond Iezzi
JPJose S. Pulido
Jose S. Pulido
ASArthur J. Sit
Arthur J. Sit

1 March 2016 in Retina
Verified
Journal Article
Closed access
SBSophie Bakri
Sophie Bakri
AOAhmed F. Omar
Ahmed F. Omar
RIRaymond Iezzi
Raymond Iezzi
KKKapil G. Kapoor
Kapil G. Kapoor
Limited data have evaluated multiple injections of the dexamethasone 700 μg implant (DEX) (Ozurdex; Allergan, Inc.) for cystoid macular edema (CME) secondary to retinal vein occlusion (RVO) over an extended regimen. This retrospective study evaluated patients treated with DEX for CME associated with RVO. Each patient had ophthalmologic evaluation, optical coherence tomography (OCT), and 4 weeks to 6 weeks follow-up intervals. Retreatment criterion was fluid on OCT. Outcome measures included best-corrected visual acuity, intraocular pressure (IOP), central macular thickness on OCT, fluid resolution on OCT, and required treatment for elevated IOP and cataract. Thirty-one patients had 82 DEX injections, with 19 patients having ≥2, 12 having ≥3, 10 having ≥4, 6 having ≥5, and 4 having ≥6 DEX injections. All patients were followed at least 12 weeks and had a mean follow-up period of 344.94 days. Fourteen patients (45%) developed ocular hypertension (≥22 mmHg), and 40% of phakic patients required cataract surgery. Mean interval of OCT fluid resolution was 52 days (range, 28-245; SD, ±8), and mean retreatment interval was 119 days (range, 42-309; SD, ±9). No patients required glaucoma surgery or developed endophthalmitis. This study suggests that repeated, as needed, DEX injections for CME associated with RVO may be performed. Patients should be monitored and treated for ocular hypertension and cataract progression.